Abbas Hussain has joined Board of Directors at Immunocore – T cell receptor company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases – as a Non-Executive Director. Ian Clark has also joined as a special adviser to the Board of Immunocore.
Abbas Hussain
Abbas Hussain was most recently President of Global Pharmaceuticals at GlaxoSmithKline (GSK), where he had overall responsibility for the company's sales business.
He also led operations supporting commercial infrastructure including medical, finance, human resources, IT, legal and communications.
Abbas chaired GSK's pharmaceutical operations committee, driving key decisions on commercial strategy. He was on the Board of ViiV Healthcare, GSK's HIV-specialised business uni
Abbas previously served as GSK's President of Emerging Markets, where he was responsible for building the world's leading emerging markets pharmaceuticals business by volume.
He was also responsible for driving the implementation of a new commercial operating model across more than 100 countries, helping to improve the transparency of GSK's work with healthcare professionals.
Prior to joining GSK, Abbas served in a number of roles at Eli Lilly, eventually as head of European operations.
Ian Clark
Ian Clark, former Chief Executive Officer, Head of North American Commercial Operations and member of the Board of Directors for Genentech (part of Roche Holding) is supporting the Board of Immunocore as a special adviser.
Clark joined Genentech in 2003 and has served in a number of senior roles, including Head of Global Product Strategy and Chief Marketing Officer for Roche. Ian currently serves on the Board of Kite Pharma.
